123 related articles for article (PubMed ID: 35817649)
1. Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy core.
Hoeh B; Flammia RS; Hohenhorst L; Sorce G; Chierigo F; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
Urol Oncol; 2022 Sep; 40(9):407.e9-407.e19. PubMed ID: 35817649
[TBL] [Abstract][Full Text] [Related]
2. Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients.
Hoeh B; Flammia RS; Hohenhorst L; Sorce G; Chierigo F; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Kluth LA; Mandel P; Becker A; Chun FKH; Karakiewicz PI
Prostate; 2022 May; 82(6):687-694. PubMed ID: 35188982
[TBL] [Abstract][Full Text] [Related]
3. Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer.
Hoeh B; Flammia R; Hohenhorst L; Sorce G; Chierigo F; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
Prostate Int; 2022 Mar; 10(1):21-27. PubMed ID: 35261911
[TBL] [Abstract][Full Text] [Related]
4. Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients.
Flammia RS; Hoeh B; Hohenhorst L; Sorce G; Chierigo F; Panunzio A; Tian Z; Saad F; Leonardo C; Briganti A; Antonelli A; Terrone C; Shariat SF; Anceschi U; Graefen M; Chun FKH; Montorsi F; Gallucci M; Karakiewicz PI
Int Urol Nephrol; 2022 Oct; 54(10):2521-2528. PubMed ID: 35838831
[TBL] [Abstract][Full Text] [Related]
5. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.
Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2022 Jan; 40(1):103-110. PubMed ID: 34436637
[TBL] [Abstract][Full Text] [Related]
6. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.
Yang DD; Mahal BA; Muralidhar V; Nezolosky MD; Vastola ME; Labe SA; Boldbaatar N; King MT; Martin NE; Orio PF; Beard CJ; Hoffman KE; Trinh QD; Spratt DE; Feng FY; Nguyen PL
Eur Urol Focus; 2019 Jan; 5(1):69-76. PubMed ID: 28753811
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility.
Schiffmann J; Wenzel P; Salomon G; Budäus L; Schlomm T; Minner S; Wittmer C; Kraft S; Krech T; Steurer S; Sauter G; Beyer B; Boehm K; Tilki D; Michl U; Huland H; Graefen M; Karakiewicz PI
Urol Oncol; 2015 Jul; 33(7):329.e13-9. PubMed ID: 25960411
[TBL] [Abstract][Full Text] [Related]
8. Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates.
Sorce G; Flammia RS; Hoeh B; Chierigo F; Hohenhorst L; Panunzio A; Stabile A; Gandaglia G; Tian Z; Tilki D; Terrone C; Gallucci M; Chun FKH; Antonelli A; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
Prostate; 2022 Jun; 82(10):1040-1050. PubMed ID: 35365851
[TBL] [Abstract][Full Text] [Related]
9. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.
Yang DD; Mahal BA; Muralidhar V; Vastola ME; Boldbaatar N; Labe SA; Nezolosky MD; Orio PF; King MT; Martin NE; Mouw KW; Trinh QD; Nguyen PL
Clin Genitourin Cancer; 2018 Jun; 16(3):226-234. PubMed ID: 29196209
[TBL] [Abstract][Full Text] [Related]
10. No detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favourable intermediate-risk prostate cancer: implications for active surveillance.
Herkommer K; Maier N; Ankerst DP; Schiele S; Gschwend JE; Meissner VH
World J Urol; 2021 Jul; 39(7):2499-2506. PubMed ID: 33048258
[TBL] [Abstract][Full Text] [Related]
11. Combined multiple clinical characteristics for prediction of discordance in grade and stage in prostate cancer patients undergoing systematic biopsy and radical prostatectomy.
Liu H; Tang K; Xia D; Peng E; Wang L; Chen Z
Pathol Res Pract; 2020 Nov; 216(11):153235. PubMed ID: 33035728
[TBL] [Abstract][Full Text] [Related]
12. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
Caster JM; Falchook AD; Hendrix LH; Chen RC
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
[TBL] [Abstract][Full Text] [Related]
13. Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.
Flood TA; Schieda N; Keefe DT; Breau RH; Morash C; Hogan K; Belanger EC; Mai KT; Robertson SJ
Virchows Arch; 2016 Sep; 469(3):313-9. PubMed ID: 27394432
[TBL] [Abstract][Full Text] [Related]
14. Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance.
Jeon HG; Yoo JH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM; Ferrari M; Brooks JD; Chung BI
PLoS One; 2017; 12(11):e0186026. PubMed ID: 29136019
[TBL] [Abstract][Full Text] [Related]
15. Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy.
Gao Y; Jiang CY; Mao SK; Cui D; Hao KY; Zhao W; Jiang Q; Ruan Y; Xia SJ; Han BM
Asian J Androl; 2016; 18(4):639-43. PubMed ID: 26732103
[TBL] [Abstract][Full Text] [Related]
16. Histologic upgrading in patients eligible for active surveillance on saturation biopsy.
Chung PH; Darwish OM; Roehrborn CG; Kapur P; Lotan Y
Can J Urol; 2015 Feb; 22(1):7656-60. PubMed ID: 25694015
[TBL] [Abstract][Full Text] [Related]
17. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
[TBL] [Abstract][Full Text] [Related]
18. Optimizing patient selection for prostate monotherapy.
Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Prostate Cancer Upgrading and Upstaging on Biochemical Recurrence and Cancer-Specific Survival.
Bakavičius A; Drevinskaitė M; Daniūnaitė K; Barisienė M; Jarmalaitė S; Jankevičius F
Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32033148
[No Abstract] [Full Text] [Related]
20. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
